Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

Bo Han, Rohit Mehra, Robert J. Lonigro, Lei Wang, Khalid Suleman, Anjana Menon, Nallasivam Palanisamy, Scott A. Tomlins, Arul M. Chinnaiyan, Rajal B. Shah

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgen-independent metastatic prostate cancer patients. Overall, ERG rearrangement was present in 15% (5/33) of HGPIN, 45% (121/267) of localized cancers and 35% (15/43) of metastases. By contrast, PTEN deletion was identified in 9% (3/33) of HGPIN, 17% (42/251) of localized cancers and 54% (22/41) of metastases, of which 0%, 40% (17/42) and 45% (10/22) were homozygous, respectively. Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN. Significantly, association between PTEN deletion and ERG rearrangement was present both in localized cancers (P0.0008) and metastases (P0.02). Further, immunohistochemistry revealed significant correlation of decreased PTEN protein expression with PTEN genomic deletion both in localized and metastatic cancer. Of note, ERG aberration, but not PTEN deletion, was consistently identical both in localized cancer and adjacent HGPIN. Similarly, whereas all metastases (41/41, 100%) shared the same ERG status across multiple sites from the same patient, 5% (2/41) of cases showed discordance for PTEN deletion status across multiple sites. Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, presumably a second hit after ERG rearrangement. PTEN deletion and ERG rearrangement may cooperate, but contribute at different stages, in prostate cancer progression.

Original languageEnglish (US)
Pages (from-to)1083-1093
Number of pages11
JournalModern Pathology
Volume22
Issue number8
DOIs
StatePublished - Aug 1 2009
Externally publishedYes

Fingerprint

Prostatic Intraepithelial Neoplasia
Fluorescence In Situ Hybridization
Prostatic Neoplasms
PTEN Phosphohydrolase
Neoplasm Metastasis
Neoplasms
Chromosomes, Human, Pair 10
Chromosome Deletion
Androgens
Prostate
Immunohistochemistry

Keywords

  • Deletion
  • ERG
  • Fluorescence in situ hybridization
  • Prostate cancer
  • PTEN
  • Rearrangement

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. / Han, Bo; Mehra, Rohit; Lonigro, Robert J.; Wang, Lei; Suleman, Khalid; Menon, Anjana; Palanisamy, Nallasivam; Tomlins, Scott A.; Chinnaiyan, Arul M.; Shah, Rajal B.

In: Modern Pathology, Vol. 22, No. 8, 01.08.2009, p. 1083-1093.

Research output: Contribution to journalArticle

Han, B, Mehra, R, Lonigro, RJ, Wang, L, Suleman, K, Menon, A, Palanisamy, N, Tomlins, SA, Chinnaiyan, AM & Shah, RB 2009, 'Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression', Modern Pathology, vol. 22, no. 8, pp. 1083-1093. https://doi.org/10.1038/modpathol.2009.69
Han, Bo ; Mehra, Rohit ; Lonigro, Robert J. ; Wang, Lei ; Suleman, Khalid ; Menon, Anjana ; Palanisamy, Nallasivam ; Tomlins, Scott A. ; Chinnaiyan, Arul M. ; Shah, Rajal B. / Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. In: Modern Pathology. 2009 ; Vol. 22, No. 8. pp. 1083-1093.
@article{775ed4a601d14727aba8510d2b85232f,
title = "Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression",
abstract = "The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgen-independent metastatic prostate cancer patients. Overall, ERG rearrangement was present in 15{\%} (5/33) of HGPIN, 45{\%} (121/267) of localized cancers and 35{\%} (15/43) of metastases. By contrast, PTEN deletion was identified in 9{\%} (3/33) of HGPIN, 17{\%} (42/251) of localized cancers and 54{\%} (22/41) of metastases, of which 0{\%}, 40{\%} (17/42) and 45{\%} (10/22) were homozygous, respectively. Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN. Significantly, association between PTEN deletion and ERG rearrangement was present both in localized cancers (P0.0008) and metastases (P0.02). Further, immunohistochemistry revealed significant correlation of decreased PTEN protein expression with PTEN genomic deletion both in localized and metastatic cancer. Of note, ERG aberration, but not PTEN deletion, was consistently identical both in localized cancer and adjacent HGPIN. Similarly, whereas all metastases (41/41, 100{\%}) shared the same ERG status across multiple sites from the same patient, 5{\%} (2/41) of cases showed discordance for PTEN deletion status across multiple sites. Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, presumably a second hit after ERG rearrangement. PTEN deletion and ERG rearrangement may cooperate, but contribute at different stages, in prostate cancer progression.",
keywords = "Deletion, ERG, Fluorescence in situ hybridization, Prostate cancer, PTEN, Rearrangement",
author = "Bo Han and Rohit Mehra and Lonigro, {Robert J.} and Lei Wang and Khalid Suleman and Anjana Menon and Nallasivam Palanisamy and Tomlins, {Scott A.} and Chinnaiyan, {Arul M.} and Shah, {Rajal B.}",
year = "2009",
month = "8",
day = "1",
doi = "10.1038/modpathol.2009.69",
language = "English (US)",
volume = "22",
pages = "1083--1093",
journal = "Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression

AU - Han, Bo

AU - Mehra, Rohit

AU - Lonigro, Robert J.

AU - Wang, Lei

AU - Suleman, Khalid

AU - Menon, Anjana

AU - Palanisamy, Nallasivam

AU - Tomlins, Scott A.

AU - Chinnaiyan, Arul M.

AU - Shah, Rajal B.

PY - 2009/8/1

Y1 - 2009/8/1

N2 - The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgen-independent metastatic prostate cancer patients. Overall, ERG rearrangement was present in 15% (5/33) of HGPIN, 45% (121/267) of localized cancers and 35% (15/43) of metastases. By contrast, PTEN deletion was identified in 9% (3/33) of HGPIN, 17% (42/251) of localized cancers and 54% (22/41) of metastases, of which 0%, 40% (17/42) and 45% (10/22) were homozygous, respectively. Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN. Significantly, association between PTEN deletion and ERG rearrangement was present both in localized cancers (P0.0008) and metastases (P0.02). Further, immunohistochemistry revealed significant correlation of decreased PTEN protein expression with PTEN genomic deletion both in localized and metastatic cancer. Of note, ERG aberration, but not PTEN deletion, was consistently identical both in localized cancer and adjacent HGPIN. Similarly, whereas all metastases (41/41, 100%) shared the same ERG status across multiple sites from the same patient, 5% (2/41) of cases showed discordance for PTEN deletion status across multiple sites. Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, presumably a second hit after ERG rearrangement. PTEN deletion and ERG rearrangement may cooperate, but contribute at different stages, in prostate cancer progression.

AB - The link between ERG rearrangement and PTEN (phosphatase and tensin homolog deleted on chromosome 10) deletion is unclear in prostate cancer progression. Using fluorescence in situ hybridization, we systematically validated the frequency and distribution of ERG and PTEN aberrations in a cohort of 73 benign prostate tissues, 59 high-grade prostatic intraepithelial neoplasia (HGPIN) foci, 281 localized prostate cancer and 47 androgen-independent metastatic prostate cancer patients. Overall, ERG rearrangement was present in 15% (5/33) of HGPIN, 45% (121/267) of localized cancers and 35% (15/43) of metastases. By contrast, PTEN deletion was identified in 9% (3/33) of HGPIN, 17% (42/251) of localized cancers and 54% (22/41) of metastases, of which 0%, 40% (17/42) and 45% (10/22) were homozygous, respectively. Concomitance of ERG rearrangement and PTEN deletion was observed in a subset of HGPIN. Significantly, association between PTEN deletion and ERG rearrangement was present both in localized cancers (P0.0008) and metastases (P0.02). Further, immunohistochemistry revealed significant correlation of decreased PTEN protein expression with PTEN genomic deletion both in localized and metastatic cancer. Of note, ERG aberration, but not PTEN deletion, was consistently identical both in localized cancer and adjacent HGPIN. Similarly, whereas all metastases (41/41, 100%) shared the same ERG status across multiple sites from the same patient, 5% (2/41) of cases showed discordance for PTEN deletion status across multiple sites. Collectively, our data support PTEN deletion as a late genetic event in human prostate cancer, presumably a second hit after ERG rearrangement. PTEN deletion and ERG rearrangement may cooperate, but contribute at different stages, in prostate cancer progression.

KW - Deletion

KW - ERG

KW - Fluorescence in situ hybridization

KW - Prostate cancer

KW - PTEN

KW - Rearrangement

UR - http://www.scopus.com/inward/record.url?scp=68249083702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249083702&partnerID=8YFLogxK

U2 - 10.1038/modpathol.2009.69

DO - 10.1038/modpathol.2009.69

M3 - Article

C2 - 19407851

AN - SCOPUS:68249083702

VL - 22

SP - 1083

EP - 1093

JO - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

SN - 0893-3952

IS - 8

ER -